PLUS THERAPEUTICS INC (PSTV)
US72941H5090 - Common Stock
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense...
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic...
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plus Therapeutics (NASDAQ:PSTV) just reported results for the fourth quarter of...
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for...
Plus sees an additional $6.9M in grant revenue in 2024 (NASDAQ:PSTV)
Plus Therapeutics expects an additional $6.9 million in grant revenue in 2024, along with a lower interest rate and deferred principal payments on a debt...
Plus Updates Financial and Cash Guidance for 2024
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing...
Plus Therapeutics files to sell ordinary shares, warrants (NASDAQ:PSTV)
Plus Therapeutics files prospectus for sale of ordinary shares and pre-funded warrants. This is not an offer to sell securities.
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Plus Therapeutics stock jumps on $500,000 share repurchase program (NASDAQ:PSTV)
Plus Therapeutics (PSTV) approves share repurchase program worth $500k, leading to a 4.1% rise in extended trading.
Plus Therapeutics Announces Share Repurchase Program
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting...
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5...
Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October
AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Plus Therapeutics gets $1.9M advance payment from CPRIT (NASDAQ:PSTV)
Plus Therapeutics (PSTV) said Monday that the company in August received an advance payment of about $1.9 million as part of its overall $17.6 million award contract with CPRIT
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today!